{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:53:59Z","timestamp":1791500039093,"version":"4.3.4"},"reference-count":102,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.drudis.2026.104807","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:46:58Z","timestamp":1789746418000},"page":"104807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging the translational gap in drug repurposing for rare diseases: clinical success versus regulatory conversion"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6473-1307","authenticated-orcid":false,"given":"Wael","family":"Khazen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2863-5083","authenticated-orcid":false,"given":"Samantha","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Corriol-Rohou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresinha","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3374-6274","authenticated-orcid":false,"given":"Xavier","family":"Nissan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mejat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104807_b0005","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1651-2227.2012.02705.x","article-title":"The need for worldwide policy and action plans for rare diseases","volume":"101","author":"Forman","year":"2012","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.drudis.2026.104807_b0010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/14737167.2015.965156","article-title":"Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe","volume":"15","author":"Schlander","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.drudis.2026.104807_b0015","series-title":"Handbook of Generalized Pairwise Comparisons: Methods for Patient-Centric Analysis","first-page":"379","article-title":"Applications in rare diseases","author":"Deltuvaite-Thomas","year":"2025"},{"key":"10.1016\/j.drudis.2026.104807_b0020","unstructured":"Global Genes. RARE Disease Facts. https:\/\/globalgenes.org\/rare-disease-facts\/. Accessed September 16, 2025."},{"key":"10.1016\/j.drudis.2026.104807_b0025","doi-asserted-by":"crossref","first-page":"9610","DOI":"10.4081\/ejtm.2021.9610","article-title":"Evaluation of orphan diseases global burden","volume":"31","author":"Makarova","year":"2021","journal-title":"Eur J Transl Myol"},{"key":"10.1016\/j.drudis.2026.104807_b0030","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70215","article-title":"Unlocking the mysteries of rare disease drug development: a beginner\u2019s guide for clinical pharmacologists","volume":"18","author":"Ahmed","year":"2025","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.drudis.2026.104807_b0035","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3345\/cep.2023.00535","article-title":"Development of orphan drugs for rare diseases","volume":"67","author":"Yoo","year":"2024","journal-title":"Clin Exp Pediatr"},{"key":"10.1016\/j.drudis.2026.104807_b0040","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks?","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104807_b0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104807_b0050","doi-asserted-by":"crossref","first-page":"234","DOI":"10.30574\/wjbphs.2024.20.2.0845","article-title":"The future of medicine: strategic insights into drug repurposing","volume":"20","author":"Aravanan","year":"2024","journal-title":"World J Biol Pharm Health Sci"},{"key":"10.1016\/j.drudis.2026.104807_b0055","article-title":"Drug repurposing: then, now, and in the future","volume":"1","author":"Mucke","year":"2024","journal-title":"DrugRepo"},{"key":"10.1016\/j.drudis.2026.104807_b0060","article-title":"Accelerating drug development: unleashing the power of drug repurposing","volume":"1","author":"Pauly","year":"2024","journal-title":"DrugRepo"},{"key":"10.1016\/j.drudis.2026.104807_b0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tips.2021.01.003","article-title":"Drug repurposing for rare diseases","volume":"42","author":"Roessler","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2026.104807_b0070","series-title":"Drug Repurposing\u2014Hypothesis, Molecular Aspects and Therapeutic Applications","first-page":"1","article-title":"Drug repurposing and orphan disease therapeutics","author":"Dhir","year":"2020"},{"key":"10.1016\/j.drudis.2026.104807_b0075","unstructured":"Minist\u00e8re de l'Enseignement sup\u00e9rieur et de la Recherche. scanR: Project INCa-8496\u2014Evaluation du repositionnement de m\u00e9dicaments dans les cancers. scanR Website. https:\/\/scanr.enseignementsup-recherche.gouv.fr\/projects\/INCa-8496. Accessed December 2, 2025."},{"key":"10.1016\/j.drudis.2026.104807_b0080","unstructured":"Wood L. Effect of oral propranolol on mRNA expression in symptomatic cavernous malformation. ClinicalTrials.gov Website. https:\/\/clinicaltrials.gov\/study\/NCT03474614. Published March 22, 2018. Updated April 19, 2024. Accessed December 2, 2025."},{"key":"10.1016\/j.drudis.2026.104807_b0085","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa1404710","article-title":"A randomized, controlled trial of oral propranolol in infantile hemangioma","volume":"372","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104807_b0090","unstructured":"Massachusetts Eye and Ear Infirmary. Propranolol administration in pediatric patients with recurrent respiratory papillomatosis. ClinicalTrials.gov Website. https:\/\/clinicaltrials.gov\/study\/NCT01058317. Published January 28, 2010. Updated November 21, 2013. Accessed December 2, 2025."},{"key":"10.1016\/j.drudis.2026.104807_b0095","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12890-017-0374-x","article-title":"Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension","volume":"17","author":"Vizza","year":"2017","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.drudis.2026.104807_b0100","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ana.24214","article-title":"Sildenafil does not improve cardiomyopathy in Duchenne\/Becker muscular dystrophy","volume":"76","author":"Leung","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.drudis.2026.104807_b0105","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1474-4422(24)00373-9","article-title":"Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"23","author":"Koch","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2026.104807_b0110","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14877","article-title":"Blood pressure\u2010independent inhibition of Marfan aortic root widening by the angiotensin II receptor blocker valsartan","volume":"9","author":"Tehrani","year":"2021","journal-title":"Physiol Rep"},{"key":"10.1016\/j.drudis.2026.104807_b0115","article-title":"Endothelin receptor antagonists for pulmonary arterial hypertension","volume":"3","author":"Liu","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.drudis.2026.104807_b0120","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1212\/WNL.0000000000004570","article-title":"A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy","volume":"89","author":"Victor","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2026.104807_b0125","unstructured":"Nishizawa T. Carvedilol for the prevention of minor cardiac damage and cardiac function in Duchenne muscular dystrophy. ClinicalTrials.gov Website. https:\/\/clinicaltrials.gov\/study\/NCT00606775. Published February 5, 2008. Updated February 5, 2008. Accessed December 2, 2025."},{"key":"10.1016\/j.drudis.2026.104807_b0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.3063","article-title":"Intravenous immunoglobulin alone for coronary artery lesion treatment of Kawasaki disease: a randomized clinical trial","volume":"8","author":"Kuo","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.drudis.2026.104807_b0135","unstructured":"American Epilepsy Society. Efficacy and safety of rapamycin in children with drug-resistant epilepsy associated with tuberous sclerosis complex. American Epilepsy Society Website. https:\/\/aesnet.org\/abstractslisting\/efficacy-and-safety-of-rapamycin-in-children-with-drug-resistant-epilepsy-associated-with-tuberous-sclerosis-complex. Published November 21, 2020. Accessed November 25, 2025."},{"key":"10.1016\/j.drudis.2026.104807_b0140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","article-title":"Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multi-institutional trial","volume":"127","author":"Bride","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104807_b0145","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104807_b0150","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41436-018-0297-9","article-title":"Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum","volume":"21","author":"Parker","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.drudis.2026.104807_b0155","unstructured":"Shanghai Children's Medical Center. Sirolimus in the treatment for propranolol-resistant infantile hepatic hemangioendothelioma. ClinicalTrials.gov Website. https:\/\/clinicaltrials.gov\/study\/NCT04406870. Published May 29, 2020. Updated May 29, 2020. Accessed December 2, 2025."},{"key":"10.1016\/j.drudis.2026.104807_b0160","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2141.2010.08096.x","article-title":"Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria","volume":"149","author":"Hill","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.drudis.2026.104807_b0165","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104807_b0170","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104807_b0175","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.gastro.2010.05.001","article-title":"Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial","volume":"139","author":"Dohil","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2026.104807_b0180","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ahj.2010.10.038","article-title":"Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA)","volume":"161","author":"Lagedrost","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.drudis.2026.104807_b0185","article-title":"Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: the LEROS nonrandomized controlled trial","volume":"5","author":"Yu-Wai-Man","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.drudis.2026.104807_b0190","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.nmd.2016.12.014","article-title":"Characterization of pulmonary function in 10\u201318 year old patients with Duchenne muscular dystrophy","volume":"27","author":"Meier","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.drudis.2026.104807_b0195","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/jmg-2024-109951","article-title":"Clonazepam repurposing in ARID1B patients through conventional RCT and N-of-1 trials: an experimental strategy for orphan disease development","volume":"62","author":"van der Sluijs","year":"2025","journal-title":"J Med Genet"},{"key":"10.1016\/j.drudis.2026.104807_b0200","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.35841","article-title":"Safety and efficacy of acetyl-DL-leucine in certain types of cerebellar ataxia: the ALCAT Randomized Clinical Crossover Trial","volume":"4","author":"Feil","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.drudis.2026.104807_b0205","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/13506129.2019.1597702","article-title":"Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study","volume":"26","author":"Gamez","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.drudis.2026.104807_b0210","unstructured":"Istituto Di Ricovero E Cura A Carattere Scientifico Materno Infantile Burlo Garofolo. Study on perampanel for improving behavior and quality of life in patients with White\u2013Sutton syndrome. European Union Clinical Trials Website. https:\/\/clinicaltrials.eu\/trial\/study-on-perampanel-for-improving-behavior-and-quality-of-life-in-patients-with-white-sutton-syndrome\/. Accessed June 9, 2026."},{"key":"10.1016\/j.drudis.2026.104807_b0215","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1320710","article-title":"Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial","volume":"13","author":"Pace","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2026.104807_b0220","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/21678421.2023.2260838","article-title":"Describing and characterising variability in ALS disease progression","volume":"25","author":"Din Abdul Jabbar","year":"2024","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.drudis.2026.104807_b0225","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2310151","article-title":"Trial of N-acetyl-l-leucine in Niemann\u2013Pick Disease Type C","volume":"390","author":"Bremova-Ertl","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104807_b0230","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/jnnp-2023-332106","article-title":"Effect of sodium phenylbutyrate and taurursodiol on plasma concentrations of neuroinflammatory biomarkers in amyotrophic lateral sclerosis: results from the CENTAUR trial","volume":"95","author":"Bowser","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.drudis.2026.104807_b0235","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-091495","article-title":"Sodium valproate, a potential repurposed treatment for the neurodegeneration in Wolfram syndrome (TREATWOLFRAM): trial protocol for a pivotal multicentre, randomised double-blind controlled trial","volume":"15","author":"Dias","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.drudis.2026.104807_b0240","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/jamaneurol.2020.4300","article-title":"Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial","volume":"78","author":"Wainger","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.drudis.2026.104807_b0245","unstructured":"DrugBank. Fenfluramine completed phase 3 trials for Dravet syndrome (DS)\/seizure disorders treatment. DrugBank Online Website. https:\/\/go.drugbank.com\/drugs\/DB00574\/clinical_trials?conditions=DBCOND0140482%2CDBCOND0054372&phase=3&purpose=treatment&status=completed. Accessed November 25, 2025."},{"key":"10.1016\/j.drudis.2026.104807_b0250","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S1474-4422(23)00285-5","article-title":"Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Henzi","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2026.104807_b0255","unstructured":"Orphanet. EPIK-P2: a phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS). Orphanet Website. www.orpha.net\/en\/research-trials\/clinical-trial\/625040. Accessed November 25, 2025."},{"key":"10.1016\/j.drudis.2026.104807_b0260","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-082142","article-title":"Protocol for a phase 2 study of bosutinib for amyotrophic lateral sclerosis using real-world data: induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (iDReAM) study","volume":"14","author":"Imamura","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.drudis.2026.104807_b0265","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12885-023-11797-z","article-title":"A phase Ib\/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol","volume":"24","author":"Mastall","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drudis.2026.104807_b0270","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2026.104807_b0275","doi-asserted-by":"crossref","first-page":"17704","DOI":"10.1038\/s41598-025-00547-9","article-title":"Treatment of overactive KATP channels with glibenclamide in a zebrafish model and a clinical trial in humans with Cant\u00fa syndrome","volume":"15","author":"Kleinendorst","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104807_b0280","unstructured":"Snow Foundation. Preliminary results on the Tirzepatide monotherapy in Wolfram syndrome trial\u2014virtual global research and trial updates. The Snow Foundation Website. https:\/\/thesnowfoundation.org\/tirzepatide-monotherapy-in-wolfram-syndrome-trial-preliminary-results\/. Published November 8, 2025. Updated November 16, 2025. Accessed November 25, 2025."},{"key":"10.1016\/j.drudis.2026.104807_b0285","unstructured":"Australian New Zealand Clinical Trials Registry. Pilot study of medication repurposing for idiopathic intracranial hypertension (ACTRN12625000401459). ANZCTR Website. https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12625000401459. Published May 2, 2025. Accessed November 25, 2025."},{"key":"10.1016\/j.drudis.2026.104807_b0290","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ymgme.2011.04.016","article-title":"A 3-year randomized therapeutic trial of nitisinone in alkaptonuria","volume":"103","author":"Introne","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.drudis.2026.104807_b0295","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/mus.21758","article-title":"A randomized trial of coenzyme Q10 in mitochondrial disorders","volume":"42","author":"Glover","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.drudis.2026.104807_b0300","unstructured":"Giorgino DR. A phase II randomized controlled study of miglustat in adult and juvenile patients with Niemann-Pick type C disease. ClinicalTrials.gov Website. https:\/\/clinicaltrials.gov\/study\/NCT00517153. Published August 16, 2007. Updated February 4, 2025. Accessed December 2, 2025."},{"key":"10.1016\/j.drudis.2026.104807_b0305","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s13063-016-1503-1","article-title":"Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial","volume":"17","author":"Hafner","year":"2016","journal-title":"Trials"},{"key":"10.1016\/j.drudis.2026.104807_b0310","doi-asserted-by":"crossref","first-page":"66","DOI":"10.18231\/j.jpbs.2023.011","article-title":"Drug repurposing: a futuristic approach in drug discovery","volume":"11","author":"Khan","year":"2023","journal-title":"J Pharm Biol Sci"},{"key":"10.1016\/j.drudis.2026.104807_b0315","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"10.1016\/j.drudis.2026.104807_b0320","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J Health Econ"},{"key":"10.1016\/j.drudis.2026.104807_b0325","doi-asserted-by":"crossref","DOI":"10.3389\/fddsv.2024.1460100","article-title":"How drug repurposing can advance drug discovery: challenges and opportunities","volume":"4","author":"Pinzi","year":"2024","journal-title":"Front Drug Discov"},{"key":"10.1016\/j.drudis.2026.104807_b0330","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s43856-025-01344-1","article-title":"Impact of drug repurposing between 1985 and 2024 on pharmaceutical innovation","volume":"6","author":"Akodad","year":"2026","journal-title":"Commun Med"},{"key":"10.1016\/j.drudis.2026.104807_b0335","article-title":"Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006\u20132022)","volume":"30","author":"Schuhmacher","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104807_b0340","unstructured":"Thomas DW, Burns J, Audette J, Carroll A, Dow-Hygelund C, Hay M. Clinical development success rates 2006\u20132015. Biotechnology Innovation Organization (BIO) Website. https:\/\/go.bio.org\/rs\/490-EHZ-999\/images\/ClinicalDevelopmentSuccessRates2011_2020.pdf. Published February 2021. Accessed June 21, 2026."},{"key":"10.1016\/j.drudis.2026.104807_b0345","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: new agents, targets and indications","volume":"16","author":"Hauser","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104807_b0350","unstructured":"Novartis. FDA approves Novartis Vijoice\u00ae (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS). Novartis Website. www.novartis.com\/news\/media-releases\/fda-approves-novartis-vijoice-alpelisib-first-and-only-treatment-select-patients-pik3ca-related-overgrowth-spectrum-pros. Published April 6, 2022. Accessed June 9, 2026."},{"key":"10.1016\/j.drudis.2026.104807_b0355","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213589","article-title":"Disease-modifying, neuroprotective effect of N-acetyl-l-leucine in adult and pediatric patients with Niemann-Pick disease Type C","volume":"105","author":"Patterson","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2026.104807_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107866","article-title":"Fenfluramine repurposing from weight loss to epilepsy: what we do and do not know","volume":"226","author":"Odi","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104807_b0365","unstructured":"European Medicines Agency (EMA). First treatment for rare metabolic disorder alkaptonuria. European Medicines Agency (EMA) Website. www.ema.europa.eu\/en\/news\/first-treatment-rare-metabolic-disorder-alkaptonuria. Published September 18, 2020. Accessed February 25, 2026."},{"key":"10.1016\/j.drudis.2026.104807_b0370","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00467-018-4091-3","article-title":"Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use","volume":"34","author":"Wijnsma","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.drudis.2026.104807_b0375","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1186\/s13063-022-06713-y","article-title":"Identifying obstacles hindering the conduct of academic-sponsored trials for drug repurposing on rare-diseases: an analysis of six use cases","volume":"23","author":"del \u00c1lamo","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.drudis.2026.104807_b0380","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.xphs.2020.01.020","article-title":"Transitioning chemistry, manufacturing, and controls content with a structured data management solution: streamlining regulatory submissions","volume":"109","author":"Algorri","year":"2020","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.drudis.2026.104807_b0385","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1670845","article-title":"Overcoming barriers to off-patent drug repurposing: a lifecycle-based policy solutions","volume":"16","author":"Garcia-Diaz","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104807_b0390","series-title":"Drug Repurposing: From Molecules to Patients","first-page":"145","article-title":"Commercialising drug repurposed products: what works and what doesn\u2019t","author":"Cavalla","year":"2024"},{"key":"10.1016\/j.drudis.2026.104807_b0395","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/1078-0432.CCR-23-1270","article-title":"FDA approval summary: alpelisib for PIK3CA-related overgrowth spectrum (PROS)","volume":"30","author":"Singh","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104807_b0400","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/cpt.3428","article-title":"The rare disease moonshot: paradigms shift, translational medicine, and regulatory science for the world\u2019s rarest conditions","volume":"116","author":"Ollivier","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104807_b0405","article-title":"Drug repurposing for rare: progress and opportunities for the rare disease community","volume":"11","author":"Jonker","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.drudis.2026.104807_b0410","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1186\/s13023-025-04048-w","article-title":"Basket trials in rare diseases: a systematic review of current practices, methodological challenges, and future directions","volume":"20","author":"Khazen","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2026.104807_b0415","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12916-018-1216-2","article-title":"Patient, study thyself","volume":"16","author":"Wicks","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.drudis.2026.104807_b0420","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1158\/2159-8290.CD-22-1377","article-title":"N-of-1 trials in cancer drug development","volume":"13","author":"Gouda","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2026.104807_b0425","first-page":"693","article-title":"Advances and developments in drug repurposing; state of art","volume":"46","author":"Noori","year":"2023","journal-title":"Bull Pharm Sci Assiut"},{"key":"10.1016\/j.drudis.2026.104807_b0430","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1186\/s12913-022-08272-z","article-title":"Drug repurposing: a systematic review on root causes, barriers and facilitators","volume":"22","author":"Krishnamurthy","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.drudis.2026.104807_b0435","series-title":"Multidisciplinary Engineering Applications of Artificial Intelligence in Design Control and Infrastructure Systems","first-page":"315","article-title":"AI guided drug repurposing and predictive pharmacokinetics in early phase clinical trials","author":"Anuja","year":"2025"},{"key":"10.1016\/j.drudis.2026.104807_b0440","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104807_b0445","doi-asserted-by":"crossref","first-page":"19358","DOI":"10.1038\/s41598-023-46648-1","article-title":"A novel in silico scaffold-hopping method for drug repositioning in rare and intractable diseases","volume":"13","author":"Tanabe","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104807_b0450","unstructured":"European Medicines Agency (EMA). Repurposing of authorised medicines: pilot to support not-for-profit organisations and academia. EMA Website. www.ema.europa.eu\/en\/news\/repurposing-authorised-medicines-pilot-support-not-profit-organisations-and-academia. Published October 28, 2021. Accessed August 27, 2026."},{"key":"10.1016\/j.drudis.2026.104807_b0455","unstructured":"REMEDi4ALL Website. https:\/\/remedi4all.org\/. Accessed December 12, 2025."},{"key":"10.1016\/j.drudis.2026.104807_b0460","unstructured":"European Medicines Agency (EMA). PRIME: priority medicines. EMA Website. www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/prime-priority-medicines. Accessed August 27, 2026."},{"key":"10.1016\/j.drudis.2026.104807_b0465","unstructured":"Miglierini G. EFPIA, position paper on drug repurposing. NCF International Website. www.ncfinternational.it\/efpia-position-paper-on-drug-repurposing\/. Published April 18, 2024. Accessed February 26, 2026."},{"key":"10.1016\/j.drudis.2026.104807_b0470","unstructured":"REPO4EU. The Euro-Global platform for drug repurposing. REPO4EU Website. https:\/\/repo4.eu\/. Accessed December 12, 2025."},{"key":"10.1016\/j.drudis.2026.104807_b0475","unstructured":"SIMPATHIC Website. https:\/\/simpathic.eu\/. Accessed December 12, 2025."},{"key":"10.1016\/j.drudis.2026.104807_b0480","first-page":"1","article-title":"DREAMS: drug repurposing with artificial intelligence for muscular disorders","volume":"2","author":"Miagoux","year":"2025","journal-title":"DrugRepo"},{"key":"10.1016\/j.drudis.2026.104807_b0485","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.746987","article-title":"Drug repurposing for rare diseases: a role for academia","volume":"12","author":"van den Berg","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104807_b0490","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f6104","article-title":"Non-publication of large randomized clinical trials: cross sectional analysis","volume":"347","author":"Jones","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2026.104807_b0495","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.therap.2020.02.003","article-title":"Orphan drug designation in Europe: a booster for the research and development of drugs in rare diseases","volume":"75","author":"Micallef","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.drudis.2026.104807_b0500","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1136\/bmj.39400.376424.BE","article-title":"Regulation of drugs for children in Europe","volume":"335","author":"Choonara","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2026.104807_b0505","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/0092861512443748","article-title":"Hybrid or mixed Marketing Authorization Application in the European Union: not a trivial decision in new development programs for established drugs","volume":"46","author":"Vogel","year":"2012","journal-title":"Drug Inf J"},{"key":"10.1016\/j.drudis.2026.104807_b0510","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/jama.2015.11845","article-title":"Experience with the Priority Review Voucher program for drug development","volume":"314","author":"Kesselheim","year":"2015","journal-title":"JAMA"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:39:46Z","timestamp":1791499186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626002126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":102,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1359644626002126"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104807","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bridging the translational gap in drug repurposing for rare diseases: clinical success versus regulatory conversion","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104807","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104807"}}